:format(jpeg):focal(1376x641:1386x631)/cloudfront-us-east-1.images.arcpublishing.com/gfrmedia/HQM37ZVINZEOHLCT66SUPKBWXQ.jpg)
A multicenter study led by the Hospital Clinic de Barcelona-IDIBAPS has demonstrated the efficacy of CAR-T ARI0002h immune therapy to treat patients with multiple myeloma resistant to usual treatments.
The study, published by the magazine ‘The Lancet Oncology’, shows that all patients treated with this CAR-T, developed at the Barcelona hospital, present a response to treatment, of which close to 70% are complete after 18 months and the rest are partial.
The research, financed by the Carlos III Health Institute, the Bosch Aymerich Foundation and the La Caixa Foundation, has been coordinated by the hematologist at the Clinic Carlos Fernandez de Larrea, and the University Clinic of Navarra, the Salamanca Hospital have collaborated , the Virgen de la Arrixaca Hospital in Murcia and the Virgen del Rocio Hospital in Seville.
It is the first CAR-T (Chimeric Antigen Receptor T-Cell) developed in Europe for multiple myeloma and, according to the researchers, it is a promising option in the treatment of resistant multiple myeloma.
It is a type of cell and gene therapy in which the patient becomes his own donor and consists of modifying the patient’s T lymphocytes so that they have the ability to attack tumor cells.
“This is the second CAR-T developed at the Clinic-IDIBAPS, but the difference with respect to previous CAR-Ts, in addition to the therapeutic target, which in this case is the BCMA antigen, is that on this occasion it is humanized because many Mouse antibodies are sometimes used to develop CAR-T and In this case, we have humanized it so that it has a greater durability in the patient and a lower probability of rejection”, explained the head of the Clinic’s Immunology Service, Manel Juan.
This immunologist, who is also responsible for the joint platforms of the Sant Joan de Deu Hospital and the Blood and Tissue Bank, recalled that multiple myeloma accounts for 10% of cancers of the bone marrow, where plasma cells are found (a type of white blood cell) responsible for producing antibodies that help fight infection.
In multiple myeloma these cells undergo an abnormal growth process and form tumors in the bones.
According to oncologists, patient survival has improved thanks to incorporating certain treatments, although there is a significant proportion of patients who relapse and generate resistance to therapies.
The Clinic-IDIBAPS team has developed a new CAR-T, the ARI0002h, to treat these patients and, to evaluate its efficacy, began a trial with four other hospitals to treat 30 myeloma patients who had relapsed after two or three previous treatments. .
“Thanks to learning from previous trials with the CAR-T developed in the hospital, we saw that administering the initial divided dose could reduce the severity of the adverse effects without reducing efficacy,” Fernandez de Larrea detailed.
“Thus, the first dose is administered in three aliquots and, 100 days after the first infusion, a booster dose is administered that provides a sustained response. over time with low toxicity”, he specified.
The results show that, after a follow-up of 18 months, there is a response of all the patients to the treatment, of which 67% are complete, 27% are very good partial and 7% are partial responses.
At 3 months, in 24 of the 26 patients with bone marrow samples, no residual disease was identified, there was no neurological toxicity, and immunological adverse effects were mild, thanks in part to the administration schedule, according to Fernandez.
However, although the results are promising, patients treated with the ARI0002h continue to relapse.
“We have carried out studies that reveal that there are different mechanisms that could be responsible for the relapse after treatment with this CAR-T, and we have detected a permanence of CAR-T cells for five months in the blood and, although this time it is similar to that of other CAR-T for this disease, it is still short”, indicated Fernandez de Larrea.
“Now, our research is aimed at finding out how we can lengthen the persistence of CAR-T”, concluded the hematologist, who reported that, in addition to the 30 patients participating in this study, another 30 patients have already been included. also including two other Spanish hospitals and the treatment has been administered as compassionate use in 12 more patients.
Now, the Spanish Agency for Medicines and Health Products (AEMPS) is evaluating the documentation based on the results of this study for its approval as a non-industrially manufactured advanced therapy drug.
